Etanidazole monohydrate | CAS#182323-12-2 | 2-nitroimidazole

MedKoo Cat#: 126331 | Name: Etanidazole monohydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Etanidazole (SR-2508) is a 2-nitroimidazole drug with radiosensitizing properties. Etanidazole depletes glutathione and inhibits glutathione transferase, thereby enhancing the cytotoxicity of ionizing radiation. This agent may also be useful as an imaging agent for identifying hypoxic, drug-resistant regions of primary tumors or metastases. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Chemical Structure

Etanidazole monohydrate

CAS#182323-12-2 (hydrate)

Theoretical Analysis

MedKoo Cat#: 126331

Name: Etanidazole monohydrate

CAS#: 182323-12-2 (hydrate)

Chemical Formula: C7H12N4O5

Exact Mass: 232.0808

Molecular Weight: 232.20

Elemental Analysis: C, 36.21; H, 5.21; N, 24.13; O, 34.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

182323-12-2 (hydrate) 22668-01-5 (free base)

Synonym

Etanidazole monohydrate; Etanidazole; SR2508; SR 2508; SR-2508

IUPAC/Chemical Name

N-(2-hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide hydrate

InChi Key

VLPRXIRKJZLPHS-UHFFFAOYSA-N

InChi Code

InChI=1S/C7H10N4O4.H2O/c12-4-2-8-6(13)5-10-3-1-9-7(10)11(14)15;/h1,3,12H,2,4-5H2,(H,8,13);1H2

SMILES Code

C1=CN(C(=N1)[N+](=O)[O-])CC(=O)NCCO.O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 232.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hurwitz SJ, Coleman CN, Riese N, Loeffler JS, Alexander E 3rd, Buswell L, Neben TY, Shargel L, Kramer RA. Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas. Int J Radiat Oncol Biol Phys. 1992;22(3):573-6. doi: 10.1016/0360-3016(92)90879-m. PMID: 1531216. 2: Abe C, Uto Y, Nakae T, Shinmoto Y, Sano K, Nakata H, Teraoka M, Endo Y, Maezawa H, Masunaga S, Nakata E, Hori H. Evaluation of the in vivo radiosensitizing activity of etanidazole using tumor-bearing chick embryo. J Radiat Res. 2011;52(2):208-14. doi: 10.1269/jrr.10122. PMID: 21436611. 3: Teicher BA, Herman TS, Holden SA. Effect of pH, oxygenation, and temperature on the cytotoxicity and radiosensitization by etanidazole. Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):723-31. doi: 10.1016/0360-3016(91)90015-v. PMID: 1825994. 4: Jin C, Bai L, Wu H, Tian F, Guo G. Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro. Biomaterials. 2007 Sep;28(25):3724-30. doi: 10.1016/j.biomaterials.2007.04.032. Epub 2007 May 3. PMID: 17509678. 5: Shulman LN, Buswell L, Goodman H, Muto M, Berkowitz R, Teicher B, Kusumoto T, Hurwitz SJ, Kalish LA, Coleman CN. Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):545-8. doi: 10.1016/0360-3016(94)90453-7. PMID: 8005814. 6: Evans SM, LaCreta F, Helfand S, VanWinkle T, Curran WJ Jr, Brown DQ, Hanks G. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):703-8. doi: 10.1016/0360-3016(91)90012-s. PMID: 1825993. 7: Wang FJ, Wang CH. Sustained release of etanidazole from spray dried microspheres prepared by non-halogenated solvents. J Control Release. 2002 Jun 17;81(3):263-80. doi: 10.1016/s0168-3659(02)00066-4. PMID: 12044566. 8: Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goumnerova L, Billett AL, Kieran M, Tarbell NJ. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1182-5. doi: 10.1016/s0360-3016(02)04391-2. PMID: 12654425. 9: Stone HB, Hirst VK, Cribbs R, Luu YH, Brown JM. A comparison of radiosensitization by etanidazole and pimonidazole in mouse tumors. Int J Radiat Oncol Biol Phys. 1991 May;20(5):987-95. doi: 10.1016/0360-3016(91)90195-a. PMID: 1827089. 10: Inanami O, Sugihara K, Okui T, Hayashi M, Tsujitani M, Kuwabara M. Hypoxia and etanidazole alter radiation-induced apoptosis in HL60 cells but not in MOLT-4 cells. Int J Radiat Biol. 2002 Apr;78(4):267-74. doi: 10.1080/09553000110105695. PMID: 12020438. 11: Morilla MJ, Montanari J, Frank F, Malchiodi E, Corral R, Petray P, Romero EL. Etanidazole in pH-sensitive liposomes: design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity. J Control Release. 2005 Apr 18;103(3):599-607. doi: 10.1016/j.jconrel.2004.12.012. PMID: 15820407. 12: Shulman LN, Buswell L, Kalish LA, Coleman CN. Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):541-3. doi: 10.1016/0360-3016(94)90452-9. PMID: 8005813. 13: Wang FJ, Wang CH. Etanidazole-loaded microspheres fabricated by spray-drying different poly(lactide/glycolide) polymers: effects on microsphere properties. J Biomater Sci Polym Ed. 2003;14(2):157-83. doi: 10.1163/156856203321142597. PMID: 12661666. 14: O'Dwyer PJ, LaCreta FP. Pharmacology and clinical investigation of SR-2508 (etanidazole). Cancer Treat Res. 1991;58:45-63. doi: 10.1007/978-1-4615-3876-9_3. PMID: 1683785. 15: Aguilera TA, Giaccia AJ. The end of the hypoxic EPOch. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):895-7. doi: 10.1016/j.ijrobp.2015.01.041. PMID: 25832683. 16: Tharmalingham H, Hoskin P. Clinical trials targeting hypoxia. Br J Radiol. 2019 Jan;92(1093):20170966. doi: 10.1259/bjr.20170966. Epub 2018 Jul 6. PMID: 29979089; PMCID: PMC6435072. 17: Eschwège F, Sancho-Garnier H, Chassagne D, Brisgand D, Guerra M, Malaise EP, Bey P, Busutti L, Cionini L, N'Guyen T, Romanini A, Chavaudra J, Hill C. Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):275-81. doi: 10.1016/s0360-3016(97)00327-1. PMID: 9308928. 18: Buswell L, Recht A, Clark J, Ravikumar T, Busse PM, Coleman CN. Combined- modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):535-40. doi: 10.1016/0360-3016(94)90451-0. PMID: 8005812. 19: Bornstein BA, Herman TS, Hansen JL, Buswell L, Zouranjian PS, Fraser SM, Teicher BA, Svensson GK, Coleman CN. Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours. Int J Hyperthermia. 1995 Jul-Aug;11(4):489-99. doi: 10.3109/02656739509022484. PMID: 7594803. 20: Teicher BA, Herman TS, Holden SA, Jones SM. Addition of misonidazole, etanidazole, or hyperthermia to treatment with fluosol-DA/carbogen/radiation. J Natl Cancer Inst. 1989 Jun 21;81(12):929-34. doi: 10.1093/jnci/81.12.929. PMID: 2525198.